AstraZeneca (AZN) Stock Price, News & Analysis

Company Overview

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders. Among its well-known products are Tagrisso and Imfinzi in oncology; Farxiga for cardiovascular, kidney and metabolic conditions; Symbicort and Fasenra for respiratory diseases; and Soliris and Ultomiris for certain rare diseases. The company also develops vaccines and other biologic therapies through selected collaborations and research programs.

AstraZeneca was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group. Its shares trade on the London Stock Exchange, and its American Depositary Receipts trade on the New York Stock Exchange under the symbol AZN. Pascal Soriot has served as the company’s chief executive officer since 2012.

Key Stats

• Today's Range: $184.96 to $188.10
• 50-Day Range: $155.93 to $189.18
• 52-Week Range: $153.41 to $212.71
• Volume: 1.80 million shs
• Average Volume: 3.40 million shs
• Market Capitalization: $289.61 billion
• P/E Ratio: 26.41
• Dividend Yield: 1.16%
• Price Target: $206.67
• Consensus Rating: Moderate Buy

AstraZeneca Stock Analysis - MarketRank™

AstraZeneca scored higher than 91% of companies evaluated by MarketBeat, and ranked 44th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.84, and is based on no strong buy ratings, 16 buy ratings, 3 hold ratings, and no sell ratings.

Upside Potential

AstraZeneca has a consensus price target of $206.67, representing about 10.7% upside from its current price of $186.74.

Amount of Analyst Coverage

AstraZeneca has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 10.96%

Earnings Growth

Earnings for AstraZeneca are expected to grow by 10.96% in the coming year, from $10.22 to $11.34 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AstraZeneca is 26.41, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.82.

Price to Earnings Ratio vs. Sector

The P/E ratio of AstraZeneca is 26.41, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.24.

Price to Earnings Growth Ratio

AstraZeneca has a PEG Ratio of 1.47. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

AstraZeneca has a P/B Ratio of 5.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.20% of the float of AstraZeneca has been sold short.

Short Interest Ratio / Days to Cover

AstraZeneca has a short interest ratio ("days to cover") of 0.93, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AstraZeneca has recently decreased by 7.65%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

AstraZeneca pays a meaningful dividend of 1.15%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

AstraZeneca does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of AstraZeneca is 30.69%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, AstraZeneca will have a dividend payout ratio of 19.14% next year. This indicates that AstraZeneca will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.5 / 5
• News Sentiment: 1.25

News Sentiment

AstraZeneca has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for AstraZeneca this week, compared to 8 articles on an average week.

Search Interest

36 people have searched for AZN on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.

MarketBeat Follows

13 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is an increase of 333% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AstraZeneca insiders have not sold or bought any company stock.

Percentage Held by Institutions

20.35% of the stock of AstraZeneca is held by institutions.

Company Calendar

• Record date for 9/8 Dividend: 8/07/2026
• Ex-Dividend for 9/8 Dividend: 8/07/2026
• Dividend Payable: 9/08/2026
• Last Earnings: 10/30/2026
• Today: 11/11/2026
• 8th Annual Wolfe Research Healthcare Conference: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:AZN
• Previous Symbol: NASDAQ:AZN
• CIK: 901832
• Web: astrazeneca.com
• Phone: 011 44 20 7304 5000
• Fax: 44-12-2335-2858
• Employees: 96,100
• Year Founded: 1999

Price Target and Rating

• Average Price Target for AstraZeneca: $206.67
• High Price Target: $216.00
• Low Price Target: $198.00
• Potential Upside/Downside: +10.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.84
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): $7.07
• Trailing P/E Ratio: 26.41
• Forward P/E Ratio: 16.47
• P/E Growth: 1.47
• Net Income: $10.23 billion
• Net Margins: 17.68%
• Pretax Margin: 21.32%
• Return on Equity: 31.85%
• Return on Assets: 13.62%

Debt

• Debt-to-Equity Ratio: 0.51
• Current Ratio: 1.01
• Quick Ratio: 0.79

Sales & Book Value

• Annual Sales: $58.74 billion
• Price / Sales: 4.93
• Cash Flow: $12.75 per share
• Price / Cash Flow: 14.65
• Book Value: $33.41 per share
• Price / Book: 5.59

Miscellaneous

• Outstanding Shares: 1,550,910,000
• Free Float: N/A
• Market Cap: $289.61 billion
• Optionable: Optionable
• Beta: 0.24